Search results - 2 results

Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.

comparable to many surrounding countries. These adjusted prevalences can help estimate the cost of reimbursement of DAA s and invite Belgian policy makers to accelerate the scaling up of reimbursement, giving ...

Diagnostic hepatitis C testing of people in treatment for substance use disorders in Belgium between 2011 and 2014: a cross-sectional study.

59.1% of those with an unknown injecting status were tested for HCV, compared to 86.5% of the patients who had recently injected and 84.5% of those who had ever injected. 36.8% of the people who had ...

QR code

QR code for this page URL